MediciNova Inc (MNOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MediciNova Inc (MNOV) has a cash flow conversion efficiency ratio of -0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.70 Million) by net assets ($43.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MediciNova Inc - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how MediciNova Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MNOV current and long-term liabilities for a breakdown of total debt and financial obligations.
MediciNova Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MediciNova Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Synthaverse S.A.
WAR:SVE
|
0.072x |
|
HNA Technology Co Ltd B
SHG:900938
|
-0.009x |
|
Seres Therapeutics Inc
NASDAQ:MCRB
|
0.050x |
|
Best Agrolife Limited
NSE:BESTAGRO
|
N/A |
|
Allcargo Terminals Ltd
NSE:ATL
|
0.638x |
|
Triniti Dinamik PT Tbk
JK:TRUE
|
0.022x |
|
META WOLF AG INH O.N.
F:WOLF
|
N/A |
|
AimCore Technology Co Ltd
TWO:3615
|
0.041x |
Annual Cash Flow Conversion Efficiency for MediciNova Inc (2003–2024)
The table below shows the annual cash flow conversion efficiency of MediciNova Inc from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see MNOV company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.50 Million | $-10.64 Million | -0.203x | -70.16% |
| 2023-12-31 | $62.38 Million | $-7.43 Million | -0.119x | +35.19% |
| 2022-12-31 | $70.24 Million | $-12.91 Million | -0.184x | -63.95% |
| 2021-12-31 | $83.68 Million | $-9.38 Million | -0.112x | +26.13% |
| 2020-12-31 | $71.33 Million | $-10.83 Million | -0.152x | -24.58% |
| 2019-12-31 | $74.89 Million | $-9.12 Million | -0.122x | +2.27% |
| 2018-12-31 | $73.11 Million | $-9.11 Million | -0.125x | +30.42% |
| 2017-12-31 | $38.64 Million | $-6.92 Million | -0.179x | +5.48% |
| 2016-12-31 | $34.53 Million | $-6.55 Million | -0.190x | +13.19% |
| 2015-12-31 | $32.75 Million | $-7.15 Million | -0.218x | -688.65% |
| 2014-12-31 | $22.01 Million | $816.53K | 0.037x | +108.86% |
| 2013-12-31 | $25.43 Million | $-10.65 Million | -0.419x | +47.48% |
| 2012-12-31 | $14.88 Million | $-11.86 Million | -0.797x | -40.78% |
| 2011-12-31 | $23.50 Million | $-13.31 Million | -0.566x | +20.94% |
| 2010-12-31 | $24.70 Million | $-17.70 Million | -0.716x | -68.48% |
| 2009-12-31 | $40.01 Million | $-17.01 Million | -0.425x | +3.26% |
| 2008-12-31 | $48.04 Million | $-21.12 Million | -0.440x | +33.24% |
| 2007-12-31 | $66.61 Million | $-43.86 Million | -0.658x | -95.22% |
| 2006-12-31 | $100.98 Million | $-34.06 Million | -0.337x | -100.04% |
| 2005-12-31 | $135.71 Million | $-22.88 Million | -0.169x | +90.45% |
| 2004-12-31 | $7.67 Million | $-13.55 Million | -1.766x | -36.09% |
| 2003-12-31 | $4.57 Million | $-5.93 Million | -1.298x | -- |
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis… Read more